Philip C Robinson1, William J Taylor2, Nicola Dalbeth2. 1. From the Centre for Neurogenetics and Statistical Genomics, Queensland Brain Institute, University of Queensland, Brisbane, Queensland; Department of Rheumatology, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia; Department of Medicine, Wellington School of Medicine, University of Otago, Wellington; Bone and Joint Research Group, University of Auckland, Auckland, New Zealand.P.C. Robinson, MBChB, PhD, FRACP, Centre for Neurogenetics and Statistical Genomics, Queensland Brain Institute, University of Queensland, and Department of Rheumatology, Royal Brisbane and Women's Hospital; W.J. Taylor, MBChB, PhD, FRACP, Department of Medicine, Wellington School of Medicine, University of Otago; N. Dalbeth, MBChB, MD, FRACP, Bone and Joint Research Group, University of Auckland. philip.robinson@uq.edu.au. 2. From the Centre for Neurogenetics and Statistical Genomics, Queensland Brain Institute, University of Queensland, Brisbane, Queensland; Department of Rheumatology, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia; Department of Medicine, Wellington School of Medicine, University of Otago, Wellington; Bone and Joint Research Group, University of Auckland, Auckland, New Zealand.P.C. Robinson, MBChB, PhD, FRACP, Centre for Neurogenetics and Statistical Genomics, Queensland Brain Institute, University of Queensland, and Department of Rheumatology, Royal Brisbane and Women's Hospital; W.J. Taylor, MBChB, PhD, FRACP, Department of Medicine, Wellington School of Medicine, University of Otago; N. Dalbeth, MBChB, MD, FRACP, Bone and Joint Research Group, University of Auckland.
Abstract
OBJECTIVE: The central strategy for effective gout management is longterm urate-lowering therapy to maintain the serum urate at a level below 0.36 mmol/l. We sought to determine the prevalence of gout and the quality of care in a national Australian general practice population. METHODS: Data were from general practice point-of-care electronic records over a 5-year period (n = 1,479,449). Information was collected on patients with gout according to a validated definition. All patients who visited the same general practices over the study period formed the denominator group. We determined the estimated prevalence of gout, the frequency of allopurinol prescription, and serum urate testing, and the percentage of patients achieving a target serum urate level. RESULTS: The crude prevalence of gout in this general practice population was 1.54% (95% CI 1.52-1.56). Prevalence in men was 2.67% and in women 0.53%. Prevalence increased with age in both men and women (4.90%, 95% CI 4.82-4.99, in men > 65 yrs). Allopurinol was prescribed to 57% of patients with gout during the 5 years of the study. Only 55% of patients with gout had their serum urate tested at any time during the 5-year study period. A target serum urate concentration of < 0.36 mmol/l at any time during the 5-year study period was documented in 22.4% of all people with gout. CONCLUSION: Gout is managed poorly in Australian primary care, with low levels of allopurinol prescribing and serum urate testing. Collectively, these factors probably contribute to low achievement of serum urate targets.
OBJECTIVE: The central strategy for effective gout management is longterm urate-lowering therapy to maintain the serum urate at a level below 0.36 mmol/l. We sought to determine the prevalence of gout and the quality of care in a national Australian general practice population. METHODS: Data were from general practice point-of-care electronic records over a 5-year period (n = 1,479,449). Information was collected on patients with gout according to a validated definition. All patients who visited the same general practices over the study period formed the denominator group. We determined the estimated prevalence of gout, the frequency of allopurinol prescription, and serum urate testing, and the percentage of patients achieving a target serum urate level. RESULTS: The crude prevalence of gout in this general practice population was 1.54% (95% CI 1.52-1.56). Prevalence in men was 2.67% and in women 0.53%. Prevalence increased with age in both men and women (4.90%, 95% CI 4.82-4.99, in men > 65 yrs). Allopurinol was prescribed to 57% of patients with gout during the 5 years of the study. Only 55% of patients with gout had their serum urate tested at any time during the 5-year study period. A target serum urate concentration of < 0.36 mmol/l at any time during the 5-year study period was documented in 22.4% of all people with gout. CONCLUSION:Gout is managed poorly in Australian primary care, with low levels of allopurinol prescribing and serum urate testing. Collectively, these factors probably contribute to low achievement of serum urate targets.
Entities:
Keywords:
GOUT; PREVALENCE; QUALITY OF CARE; SERUM URATE
Authors: Irvin J Huang; Jean W Liew; Meredith B Morcos; Silu Zuo; Carol Crawford; Alison M Bays Journal: Rheumatol Int Date: 2019-05-30 Impact factor: 2.631
Authors: Nicola Dalbeth; Thomas Bardin; Michael Doherty; Frédéric Lioté; Pascal Richette; Kenneth G Saag; Alexander K So; Lisa K Stamp; Hyon K Choi; Robert Terkeltaub Journal: Nat Rev Rheumatol Date: 2017-08-10 Impact factor: 20.543
Authors: Mehmet Akif Öztürk; Rıdvan Mercan; Kevser Gök; Ahmet Mesut Onat; Bünyamin Kısacık; Gezmiş Kimyon; Ayşe Balkarlı; Arif Kaya; Veli Çobankara; Mehmet Ali Balcı; ÖmerNuri Pamuk; Gözde Yıldırım Çetin; Mehmet Sayarlıoğlu; Soner Şenel; Mehmet Engin Tezcan; Adem Küçük; Kemal Üreten; Şafak Şahin; Abdurrahman Tufan Journal: Clin Rheumatol Date: 2016-10-08 Impact factor: 2.980
Authors: Mark D Russell; Andrew I Rutherford; Benjamin Ellis; Sam Norton; Abdel Douiri; Martin C Gulliford; Andrew P Cope; James B Galloway Journal: Lancet Reg Health Eur Date: 2022-05-25
Authors: Bart Spaetgens; Tobias Pustjens; Lieke E J M Scheepers; Hein J E M Janssens; Sjef van der Linden; Annelies Boonen Journal: Clin Rheumatol Date: 2016-02-22 Impact factor: 2.980
Authors: Richard O Day; Lauren J Frensham; Amy D Nguyen; Melissa T Baysari; Eindra Aung; Annie Y S Lau; Nicholas Zwar; Jennifer Reath; Tracey Laba; Ling Li; Andrew McLachlan; William B Runciman; Rachelle Buchbinder; Robyn Clay-Williams; Enrico Coiera; Jeffrey Braithwaite; H Patrick McNeil; David J Hunter; Kevin D Pile; Ian Portek; Kenneth Mapson WIlliams; Johanna I Westbrook Journal: BMJ Open Date: 2017-10-16 Impact factor: 2.692
Authors: Meliha C Kapetanovic; Mohaned Hameed; Aleksandra Turkiewicz; Tuhina Neogi; Tore Saxne; Lennart Jacobsson; Martin Englund Journal: RMD Open Date: 2016-11-01